重症疾病后的心理韧性:一项前瞻性、多中心、观察性研究(RESIREA)
本研究为前瞻性、多中心、观察性研究,与NUTRIREA-3试验并行,在41个法国ICU纳入接受机械通气及血管活性胺类药物治疗休克的患者,于ICU入科后3个月至1年由幸存者完成CD-RISC-25、IES-R、SF-36、MSPSS及B-IPQ量表。382例纳入患者中203例(53.1%)心理韧性正常或较高(CD-RISC-25≥68);韧性患者中26例(12.8%)有中重度PTSD症状(IES-R≥24),低韧性患者中45例(25.4%)有中重度PTSD症状(p=0.002),韧性患者SF-36评分更高。与CD-RISC-25评分更高独立相关的因素为MSPSS评分更高(提示社会支持更强)(OR 1.027;95%CI 1.008-1.047;p=0.005)及B-IPQ评分更低(提示对疾病的感知更具威胁性)(OR 0.973;95%CI 0.950-0.996;p=0.02)。作者认为,加强社会支持和改善疾病感知的干预可能有助于提高心理韧性,此类干预应以减轻PTSD和改善生活质量为目标结局在试验中评估。
要点
- 382例重症幸存者中203例(53.1%)心理韧性正常或较高(CD-RISC-25≥68)。
- 韧性患者中重度PTSD症状(IES-R≥24)比例为12.8%(26例),低韧性患者为25.4%(45例)(p=0.002)。
- 韧性患者SF-36生活质量评分高于低韧性患者。
- 社会支持更强(MSPSS评分更高)与CD-RISC-25评分更高独立相关(OR 1.027;95%CI 1.008-1.047;p=0.005)。
- 对疾病感知更具威胁性(B-IPQ评分更低)与CD-RISC-25评分更高独立相关(OR 0.973;95%CI 0.950-0.996;p=0.02)。
适用人群与场景
- 在41个法国ICU招募、与NUTRIREA-3试验并行纳入的接受机械通气及血管活性胺类药物治疗休克的患者。
- 于ICU入科后3个月至1年由幸存者完成量表评估。
诊断标准与关键阈值
- 心理韧性采用Connor-Davidson韧性量表(CD-RISC-25)评估,CD-RISC-25≥68定义为心理韧性正常或较高。
- PTSD症状采用事件影响量表修订版(IES-R)评估,IES-R≥24定义为中重度PTSD症状。
- 生活质量采用SF-36量表评估;社会支持采用多维感知社会支持量表(MSPSS)评估;疾病感知采用简明疾病感知问卷(B-IPQ)评估。
研究设计与关键结果
- 研究类型:前瞻性、多中心、观察性研究,与NUTRIREA-3试验并行,在41个法国ICU招募接受机械通气及血管活性胺类药物治疗休克的患者。
- 样本量:纳入382例患者,其中203例(53.1%)心理韧性正常或较高(CD-RISC-25≥68)。
- 主要终点:韧性患者中26例(12.8%)有中重度PTSD症状(IES-R≥24),低韧性患者中45例(25.4%)有中重度PTSD症状(p=0.002)。
- 次要终点:韧性患者SF-36评分高于低韧性患者。
- 独立相关因素:与CD-RISC-25评分更高独立相关的因素为MSPSS评分更高(提示社会支持更强)(OR 1.027;95%CI 1.008-1.047;p=0.005)及B-IPQ评分更低(提示对疾病的感知更具威胁性)(OR 0.973;95%CI 0.950-0.996;p=0.02)。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果提示加强社会支持和改善疾病感知的干预可能有助于提高心理韧性。
- 作者认为,此类干预应以减轻PTSD和改善生活质量为目标结局在试验中评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Critical-illness survivors may experience post-traumatic stress disorder (PTSD) and quality-of-life impairments. Resilience may protect against psychological trauma but has not been adequately studied after critical illness. We assessed resilience and its associations with PTSD and quality of life, and also identified factors associated with greater resilience.
METHODS: This prospective, multicentre, study in patients recruited at 41 French ICUs was done in parallel with the NUTRIREA-3 trial in patients given mechanical ventilation and vasoactive amines for shock. Three months to one year after intensive-care-unit admission, survivors completed the Connor-Davidson Resilience Scale (CD-RISC-25), Impact of Event-Revised scale for PTSD symptoms (IES-R), SF-36 quality-of-life scale, Multidimensional Scale of Perceived Social Support (MSPSS), and Brief Illness Perception Questionnaire (B-IPQ).
RESULTS: Of the 382 included patients, 203 (53.1%) had normal or high resilience (CD-RISC-25 ≥ 68). Of these resilient patients, 26 (12.8%) had moderate to severe PTSD symptoms (IES-R ≥ 24) vs. 45 (25.4%) patients with low resilience (p = 0.002). Resilient patients had higher SF-36 scores. Factors independently associated with higher CD-RISC-25 scores were higher MSPSS score indicating stronger social support (OR, 1.027; 95%CI 1.008-1.047; p = 0.005) and lower B-IPQ scores indicating a more threatening perception of the illness (OR, 0.973; 95%CI 0.950-0.996; p = 0.02).
CONCLUSIONS: Resilient patients had a lower prevalence of PTSD symptoms and higher quality of life scores, compared to patients with low resilience. Higher scores for social support and illness perception were independently associated with greater resilience. Thus, our findings suggest that interventions to strengthen social support and improve illness perception may help to improve resilience. Such interventions should be evaluated in trials with PTSD mitigation and quality-of-life improvement as the target outcomes.
参考来源
- Mathieu A, Reignier J, Le Gouge A, et al. Resilience after severe critical illness: a prospective, multicentre, observational study (RESIREA). Crit Care. 2024. PMID: 38997759. doi:10.1186/s13054-024-04989-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。